FDA Approves 18F-rhPSMA-7.3 to Identify Prostate Cancer in PET Imaging
The FDA has approved 18F-rhPSMA-7.3 (Posluma) injection for use during PET scans to identify prostate-specific membrane antigens (PSMA) positive lesions for patients with prostate cancer, according to a press release from Blue Earth Diagnostics.1
The approval is based on 2 phase 3 trials, LIGHTHOUSE
The FDA has approved 18F-rhPSMA-7.3 (Posluma) injection for use during PET scans to identify prostate-specific membrane antigens (PSMA) positive lesions for patients with prostate cancer, according to a press release from Blue Earth Diagnostics.1
The approval is based on 2 phase 3 trials, LIGHTHOUSE